News Page

AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)
Subscribe to the AIDSinfo At-a-Glance
e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research.
  • FDA Updates Stribild Labeling
    On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information.

    The updated labeling for Stribild is available at the FDA website

    More information is available: 
  • Newly Identified Marker Helps Predict Tuberculosis Complications in HIV Patients
    "An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop complications from anti-HIV drugs. For unclear reasons, a subset of people with both HIV and TB experience worsening of their TB symptoms after starting antiretroviral therapy (ART) to treat HIV. The study, which appears in the October 2, 2014, issue of PLOS Pathogens, offers a better understanding of why this may occur."

    Visit the NIAID website to read the complete article.
  • FDA Updates Etravirine Labeling
    "On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs:
    • "dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir
    • "atazanavir/ritonavir
    • "boceprevir"
    The updated labeling for etravirine is available at the FDA website.

    More information is available:
  • October 15 is National Latino AIDS Awareness Day
    National Latino AIDS Awareness Day is observed annually to highlight the disproportionate burden of HIV among Hispanics/Latinos. According to the Centers for Disease Control and Prevention (CDC), Hispanics/Latinos—despite representing only 16% of the U.S. population—accounted for 21% of new HIV infections in 2010.

    Explore our National Latino AIDS Awareness Day webpage [en español] to learn more about the annual observance and to find information about HIV in the Hispanic/Latino population.
  • NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
    "An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the virus and augments other known places where broadly neutralizing antibodies (bNAbs) bind to HIV. This newly identified site on the viral spike is where a new antibody found by the scientists in an HIV-infected person binds to the virus. Called 35O22, the antibody prevents 62 percent of known HIV strains from infecting cells in the laboratory and is extremely potent, meaning even a relatively small amount of it can neutralize the virus."

    More information is available:
  • FDA Approves Two Medications to Treat HIV Infection: Cobicistat (Brand Name: Tybost) and Elvitegravir (Brand Name: Vitekta)
    "On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection."

    For more information on cobicistat, view the FDA press release.

    "On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults."

    For more information on elvitegravir, view the FDA press release.

    The labeling for both drugs will be available soon at the FDA website